IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.

Please see full Prescribing Information.

Texas is not a single preferred drug list state. Managed Medicare Part D plans may choose not to prefer QULIPTA® in the same manner as the Fee-For-Service State Medicare Part D program. The above guidance therefore refers specifically to the FFS State Medicare Part D Program ONLY.

^†Managed Markets Insight & Technology, LLC™, a trademark of MMIT. Data as of August 2024 and subject to change.

Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficiency or safety.

Reference: 1. Data on file. AbbVie Inc.

© 2024 AbbVie. All rights reserved.
All trademarks are the property of their respective owners.

US-QLP-240294  12/24